All Articles

Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.

Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.

Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.

All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.

In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.

Connect with Us on Facebook, Attend a Facebook Live Session, Listen to a Podcast, or Check Out Our Blog

This qualitative descriptive study explored the benefits of ACP as an expanded role for the ONN by describing the perspectives of appointed healthcare power of attorney (HCPOA) agents for lung cancer patients who had their ACP discussion led by an ONN.

His new price controls might have killed Amgen’s breakthrough drug for lung cancer

The CATCH for November 2022 is awarded to Sara Sanchez, BSN, RN, a complex GI oncology nurse navigator with the Sarah Cannon Cancer Institute at Medical City Plano in Texas.

To examine how SEs impacting QOL in pts with ABC are perceived.